At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 123 enrolled
Drug / intervention
Fostamatinib Disodiumdrug
Likely dose
Fostamatinib Disodium 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
In Brief
A Phase 3 clinical trial evaluating Fostamatinib Disodium for Immune Thrombocytopenic Purpura. Completed, enrolled 123 participants across 55 sites in 15 countries.
Detailed Summary
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenic Purpura
CountriesAustralia, Austria, Bulgaria, Canada, Czechia, Denmark, Hungary, Italy, Netherlands, Norway, Poland, Romania, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartOct 2014
Primary CompletionJun 2020
TodayJul 2026
First PostedMar 4, 2014
Enrollment StartOct 1, 2014
Primary CompletionJun 2, 2020
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 12.3 years ago
Interventions
Fostamatinib Disodiumdrug
Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day